Improvement of Weaning From Mechanical Ventilation by Continuous Ultrasound Monitoring of Diaphragm Excursion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-04-11

Study Completion Date

2020-10-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Justification: The diaphragm is the main inspiratory muscle. Its dysfunction therefore compromises ventilation, which is necessary for gas exchange. Diaphragmatic dysfunction is frequently observed in resuscitation patients. Diaphragm ultrasound is currently a simple and validated technique for measuring the function of the diaphragm in intensive care. However, the discontinuity of the measurements is one of the major limitations of the current, standard ultrasonic evaluation of diaphragm function. Respinor AS (Oslo, Norway) has developed an ultrasound device (known as RESPINOR DXT) for continuous quantification of diaphragmatic excursion and velocity.

Aims of the study: To evaluate the feasibility of the continuous monitoring of the diaphragmatic excursion using RESPINOR DXT in patients undergoing MV in the intensive care unit, to ensure its reliability and to establish a link between the diaphragmatic excursion and the weaning outcome of MV.

Method: In addition to continuous diaphragm monitoring by RESPINOR DXT, a daily measurement of the diaphragm excursion will be performed using a conventional ultrasound system for comparison. A daily measurement of the oesophageal pressure (Pes) and the gastric pressure (Pga) will be performed, thus allowing the calculation of the transdiaphragmatic pressure (Pdi).

Analysis: The feasibility of the measurement will be evaluated through user utility questions as well as the time spent with a signal meeting specific quality criteria. Its reliability will be studied by the concordance between the measurements of the excursion measured by RESPINOR DXT and by standard ultrasound (Bland-Altman, Passing-Bablock). It will be further evaluated by the correlation between the variations of the excursion measured by RESPINOR DXT and the Pdi variations. Receiver operating characteristic (ROC) curves will be performed to identify the optimal diaphragmatic excursion threshold for predicting weaning success and prognosis.

Hypothesis: It is anticipated that the present study will show that the continuous monitoring of diaphragm excursion by RESPINOR DXT is reliable. Further, it is anticipated that there will be a statistical link between the diaphragmatic excursion and velocity of the movement measured by RESPINOR DXT before, during and after the spontaneous breathing trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ultrasound-Assessed Diaphragmatic Dysfunction as a Predictor of Weaning Outcome

NCT04825509

Weaning Failure Sepsis

COMPLETED

Value of Diaphragm Function Predicting Weaning From Mechanical Ventilation

NCT05632822

Weaning Failure Diaphragm Defect

UNKNOWN

Lung and Diaphragm Ultrasound Evaluation During Weaning From Mechanical Ventilation in COVID-19 Patients

NCT05706441

Weaning COVID-19 Lung Ultrasound +1 more

COMPLETED

Ultrasound to Evaluate Failure of Liberation From Mechanical Ventilation

NCT02723565

Acute Respiratory Failure Respiration, Artificial Weaning

COMPLETED

Pulmonary and Cardiac Ultrasound During Weaning From Mechanical Ventilation

NCT01098773

Adult Patients Ventilated More Than 48 h Stable Respiratory and Hemodynamic Conditions for SBT Consent of Patients +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiration, Artificial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Successful weaning/extubation

Successful weaning will be defined as a patient who completes a planned 30-minute spontaneous breathing trial.

Successful extubation will be defined as a patient who completes a planned 30-minute spontaneous breathing trial and is not reintubated in the first 48 hours after extubation.

No interventions assigned to this group

Failed weaning/extubation

Failed weaning will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial.

Failed extubation will be defined as a patient who did not complete a planned 30-minute spontaneous breathing trial, in the first 48 hours after extubation are reintubated, have unplanned non-invasive ventilation (NIV) or who have a tracheostomy.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 18 years old
* Consent to participate in the study
* Affiliation to a social security scheme or entitled to it
* Invasive mechanical ventilation for ≥ 24 hours
* Richmond Agitation Sedation Scale (RASS) ≥ - 3 (Moderate sedation)
* Able to tolerate spontaneous ventilation with inspiratory support ≤ 28 cmH2O
* Absence of high-dose vasopressors defined by noradrenaline dosage \< 0.3 μg / kg / min

Exclusion Criteria

* Central or spinal neurological lesion involving central ventilatory control or its transmission
* Contraindication to the insertion of the oesophageal catheter, ie any contraindication to insertion or change of gastric tube, esophageal surgery of less than 14 days, oesophageal varices rupture of less than 4 days
* Known neuromuscular disease, curare less than 24 hours (excluding succinylcholine for rapid sequence intubation), known hemidiaphragm paralysis or suspicion of hemidiaphragm paralysis (defined by elevation) dome\> 2.5 cm compared to contralateral dome
* Patient in therapeutic limitation
* Pregnant woman, minor patient or protected adult

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No